eligibility_summary
Inclusion: 18–75, life expectancy >3 mo, advanced/metastatic solid tumors (after ≥1L failure or no standard 1L), mesothelin ≥10%, measurable lesion, tumor tissue (fresh or archival ≤6 mo, rebiopsy), prior therapy >4 wks with ≤G1 toxicity, ECOG 0–2, prior PD‑1 ok. Exclusion: autoimmune disease, active CNS mets, recent steroids/immunosuppression, severe mAb/drug allergy, ILD, uncontrolled illness, HIV, pregnant/breastfeeding, other cancers ≤3 yrs, unhealed wound >30 d, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm trial of Pan‑T booster co‑expressing mesothelin (MSLN) CAR‑T cells (autologous gene‑modified cellular therapy). The CAR targets MSLN on solid tumor cells, co‑expression of a CD40 agonist and an unspecified T‑cell costimulatory agonist is intended to enhance T‑cell activation, proliferation, persistence, and APC licensing via CD40 signaling, improving antitumor efficacy. Pre‑infusion lymphodepletion uses albumin‑bound paclitaxel (taxane, microtubule stabilizer), cyclophosphamide (alkylating agent), and fludarabine (purine analog) to create immune space and may add direct cytotoxicity. Cells/pathways targeted: MSLN+ tumor cells, CAR‑T activation (CD3ζ signaling), CD40–CD40L axis, T‑cell costimulatory pathways, host lymphodepletion to support CAR‑T expansion.